MedTrace Logo

Ursodiol in Huntington's Disease

NCT00514774 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2009-02-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of the drug ursodiol (ursodeoxycholic acid, UDCA) in people with Huntington's disease (HD) and to explore how the compound is processed by the body.

Conditions

  • Huntington Disease

Interventions

DRUG

ursodiol

ursodiol 300 mg twice daily for study days 0 through 28 ursodiol 600mg twice daily on study days 0 through 28

DRUG

placebo

placebo 600mg twice daily for study days 0 through 28

Sponsors & Collaborators

  • Huntington Study Group

    collaborator NETWORK

  • Huntington Society of Canada

    collaborator OTHER

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Penelope Hogarth, M.D. · Oregon Health and Science University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00514774 on ClinicalTrials.gov